预约演示

更新于：2025-02-08

Danazol

达那唑

更新于：2025-02-08

概要

基本信息

药物类型

小分子化药

别名

Danazol (JP17/USP/INN)、Danazol Suppositories、Optina

+ [12]

靶点

作用机制

AR激动剂(雄激素受体激动剂)

治疗领域

免疫系统疾病心血管疾病遗传病与畸形+ [5]

在研适应症

乳腺疾病子宫内膜异位症纤维囊性乳腺疾病+ [5]

非在研适应症

糖尿病性黄斑水肿乳痛症

原研机构

Sanofi

在研机构

江苏联环药业股份有限公司

Mitsubishi Tanabe Pharma Corp.

非在研机构

FemmePharma Global Healthcare, Inc.

Sanofi-Aventis U.S. LLC

Ampio Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1976-06-21),

子宫内膜异位症纤维囊性乳腺疾病遗传性血管性水肿

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H27NO2

InChIKeyPOZRVZJJTULAOH-LHZXLZLDSA-N

CAS号17230-88-5

关联

项与达那唑相关的临床试验

NCT06176911

/ Recruiting临床2期IIT

A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Comparing the Efficacy and Safety of Teriflunomide Plus Danazol in Patients With Steroid-resistant/Relapse ITP

To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP

开始日期2023-12-05

申办/合作机构

北京大学人民医院

[+9]

NCT05852847

/ Recruiting临床2期IIT

Low-dose Baricitinib Plus Danazol Versus Danazol for Patients With Steroid-resistant/Relapse Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Phase 2 Trial

This is a prospective, multicenter, randomized, controlled phase 2 trial to compare the efficacy and safety profiles in ITP patients receiving baricitinib plus danazol to those receiving danazol alone.

开始日期2023-05-16

申办/合作机构

北京大学人民医院

[+9]

NCT04873102

/ Recruiting临床2期IIT

A Phase II Single Center Single Arm Pilot Study Administering Danazol for Treatment of Cytopenias in Patients With Cirrhosis

This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.

开始日期2023-05-01

申办/合作机构

University of Southern California

100 项与达那唑相关的临床结果

登录后查看更多信息

100 项与达那唑相关的转化医学

登录后查看更多信息

100 项与达那唑相关的专利（医药）

登录后查看更多信息

3,508

项与达那唑相关的文献（医药）

2025-02-17·IMMUNOLOGICAL INVESTIGATIONS

Buserelin Promotes the Differentiation and Function of Macrophage-Colony-Stimulating Factor-Producing T Helper Cells

Article

作者: Zheng, Aini ; Jian, Lei ; Li, Hua ; Xiang, Jin-Bo

BACKGROUND:

Buserelin has been used to treat central precocious puberty (CPP). However, it could potentially result in immune dysregulation to undermine patients' health. Therefore, it is necessary to elucidate the effects of buserelin on immune cells. Here we explored buserelin-induced impacts on the differentiation and function of macrophage-colony-stimulating factor-producing T helper (ThGM) cells to uncover the immunoregulatory role of buserelin.

METHODS:

Rat CPP was induced by danazol injection followed by buserelin treatment. The frequencies of ThGM cells in the spleen and lymph nodes were evaluated by flow cytometry. ThGM cell generation and function were analyzed in cell culture assays. Cell signaling was measured by Immunoblotting.

RESULTS:

Buserelin increased the frequencies of splenic and lymph node ThGM cells. Buserelin promoted the in vitro differentiation and proliferation of ThGM cells. Buserelin-treated ThGM cells showed stronger supportive effects on other effector T helper cells. Buserelin induced the activation of the nuclear factor of activated T cells and extracellular signal-regulated kinase 1/2 in ThGM cells.

CONCLUSION:

Buserelin enhances the differentiation and function of pro-inflammatory ThGM cells, thus increasing the risk of autoimmune or inflammatory disorders. Therefore, it is necessary to monitor ThGM cells in buserelin-treated children to prevent latent immune dysregulation.

2025-02-03·MOLECULAR PHARMACEUTICS

Simulation of Antral Conditions for Estimating Drug Apparent Equilibrium Solubility after a High-Calorie, High-Fat Meal

Article

作者: Vertzoni, Maria ; Karkaletsi, Ioanna ; Reppas, Christos ; Chorianopoulou, Christina ; Dietrich, Shirin ; Bakolia, Andriani

The simulation of antral conditions for estimating drug apparent equilibrium solubility after a high-calorie, high-fat meal is challenging. In this study, (1) we measured the apparent equilibrium solubility of two model lipophilic drugs, ketoconazole and danazol, in antral aspirates collected at various time points after a minced high-calorie, high-fat meal and a glass of water 30 min after initiation of meal administration, and we designated one point estimate for ketoconazole and one point estimate for danazol; (2) we evaluated the usefulness of FeSSGF-V2 and FEDGAS pH = 3 in reproducing the two point estimates; (3) we evaluated potential compositions of FeSSGF-V3 that simulate the pH, the buffer capacity toward both less acidic and more acidic values, and the antral lipid and protein contents with easily accessible, commercially available products, and (4) we identified the most useful composition of FeSSGF-V3 for reproducing the two point estimates. For both model drugs, apparent solubility in FeSSGF-V2 and in FEDGAS pH 3 deviated substantially from the corresponding point estimate. For FeSSGF-V3, hydrochloric acid, acetates, and FEDGASbuffer pH 3 were evaluated for regulating the pH and buffer capacity, FEDGASgel was used for simulating the lipid content, and Régilait skimmed milk powder was used for simulating the protein content. Level III FeSSGF-V3 prepared with hydrochloric acid, 6.1% (w/v) Régilait, and 2.83% (w/v) FEDGASgel, i.e., one-sixth of FEDGASgel concentration in FEDGAS pH 3, was comparatively the most useful medium for point estimating ketoconazole and danazol apparent solubility in antral contents after water administration in the fed state, induced as requested by regulatory authorities in oral drug bioavailability studies. Level III FeSSGF-V3 prepared by using hydrochloric acid as the principal pH controlling species could be useful in the evaluation of food effects on drug absorption with in silico physiologically based biopharmaceutics modeling approaches and, also, with biorelevant in vitro methodologies.

2025-01-01·Journal of orthopaedic case reports

A Rare Case of Systemic Cystic Angiomatosis in an Elderly Female Initially Misdiagnosed as Vascular Neoplasm: A Case Report and Literature Review

Article

作者: Kuttiyil, Sernam ; Archa, S ; Ismail, Rashik ; Ahamed, Hamdi Nizar ; Mohan, Sandeep ; Krishnan, Rahul

Introduction: Systemic cystic angiomatosis is an exceedingly rare condition characterized by widespread cystic vascular lesions involving multiple organs. Its clinical presentation can be non-specific, often leading to diagnostic challenges. This report discusses the case of a 72-year-old female with a long-standing history of diabetes mellitus who presented with non-specific symptoms, ultimately diagnosed with systemic cystic angiomatosis after an initial misdiagnosis of vascular neoplasia. The role of advanced imaging techniques and a multidisciplinary, individualized management approach is emphasized. Case Report: A 72-year-old female with long-standing diabetes presented with non-specific symptoms, including fatigue, fever, and rashes on the upper limbs. Initial physical examination revealed anemia and severe thrombocytopenia with a leukoerythroblastic blood picture. Despite unremarkable initial imaging studies, a bone marrow biopsy suggested vascular neoplasia. Further evaluation with a positron emission tomography (PET) scan revealed multiple non-avid lytic skeletal areas and cystic liver lesions, leading to a diagnosis of systemic cystic angiomatosis. A conservative management approach with danazol and eltrombopag was adopted. The patient later developed an acute-on-chronic subdural hematoma, a severe complication of the condition. Conclusion: This case highlights the diagnostic complexity and the necessity for individualized management strategies in systemic cystic angiomatosis. It underscores the importance of considering rare diagnoses when faced with non-specific symptoms and atypical laboratory findings. Advanced imaging techniques, such as PET scans, and a multidisciplinary approach are crucial for accurate diagnosis and effective management of this rare condition. Keywords: Systemic cystic angiomatosis, vascular neoplasia, advanced imaging, positron emission tomography scan, multidisciplinary approach, individualized management, rare diagnoses, danazol, eltrombopag, subdural hematoma.

项与达那唑相关的新闻（医药）

2024-11-13

·Pharmaceutical Technology

Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s ( GSK ) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is indicated for use in patients with intermediate or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF. This approval is based on the results from the global, randomised, multicentre, double-blind Phase III MOMENTUM trial of Ojjaara. The trial compared momelotinib with danazol in symptomatic and anaemic MF patients who had previously received treatment with an approved Janus kinase inhibitor. It assessed the safety and efficacy of momelotinib in addressing various aspects of the disease, including symptom relief, reduction in blood transfusions required for anaemia, and decrease in spleen enlargement. According to the trial’s findings, Ojjaara treatment offered improvements in total symptom score, transfusion independence, and splenic response rate. The approval in Canada is also backed by further data from a patient subset in the Phase III SIMPLIFY-1 trial, which demonstrated Ojjaara’s efficacy in treating MF patients with moderate-to-severe anaemia and related symptoms. In September last year, the US Food and Drug Administration approved Ojjaara for the same indication. Initially developed by Sierra Oncology , GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. GSK Canada interim country medical director Michelle Horn said: “Treatment options for myelofibrosis-related anaemia have been limited. We are proud to offer this treatment alternative for Canadian patients to address this critical unmet need and other myelofibrosis symptoms. “With most myelofibrosis patients becoming anaemic over time, Ojjaara’s approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK’s commitment to making an impact in Canada’s haematology oncology space through innovative new treatments.”

临床3期上市批准并购临床结果生物类似药

2024-07-26

·药融云

吉利德长效HIV疗法lenacapavir预防有效率100%！博瑞医药、合源生物新药数据登上顶刊

来源：药融云新药笔记，更多新药内容点击上方名片☝︎关注药融云新药笔记。 1.吉利德长效HIV疗法lenacapavir登《新英格兰医学杂志》，每半年注射一次，100%有效！ 7月25日，吉利德科学（Gilead Sciences）公布其关键3期PURPOSE 1试验的中期分析详细结果。该公司每半年注射一次的艾滋病毒（HIV）衣壳抑制剂lenacapavir在女性中的HIV预防用途上显示出100%的有效性，相比于每日一次口服疗法以及HIV的背景发病率皆表现出显著的优效性。据此积极结果，独立数据监测委员会建议吉利德提早解盲，并提供所有受试者开放标签的lenacapavir。该试验的详细结果也同步刊登于《新英格兰医学杂志》（NEJM）当中。PURPOSE 1 是一项 3 期、双盲、随机的非劣性研究，旨在评估每半年一次皮下注射 Lenacapavir 进行暴露前预防 (PrEP) 和每日一次口服 Truvada（舒发泰®，emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF）或 Descovy（达可挥®，emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF）对 16～25 岁女性和青春期女孩的安全性和有效性的优劣。研究共纳入来自南非 25 个地点和乌干达 3 个地点的5300 多名 16～25 岁女性和青春期女孩。参与者按照 2:2:1 的比例随机分配到三组，一组每半年注射一次 Lenacapavir，一组接受每日一次口服 Descovy，另一组每日一次口服 Truvada。结果显示，在 Lenacapavir 组的 2134 名女性中，HIV 感染病例为 0（incidence 0.00 per 100 person-years）；在 Truvada 组 1068 名女性中， HIV 感染病例为 16 例（incidence 1.69 per 100 person-years）。每半年一次的 Lenacapavir 优于 bHIV（incidence 2.41 per 100 person-years）和Truvada，同时达到主要终点和次要终点（两个终点的 p<0.0001）。Lenacapavir（商品名Sunlenca）是一种“first-in-class”长效HIV衣壳抑制剂，可以干扰HIV病毒衣壳蛋白的组装和拆卸，在HIV-1生命周期的多个阶段发挥作用，一旦获批，将成为首款每年仅需使用两次的HIV暴露前预防（PrEP）疗法。 2.博瑞医药GLP-1R/GIPR激动剂BGM0504临床前结果在Nature子刊发表 7月19日，来自博瑞医药及武汉理工大学的研究团队在Nature子刊Scientific Reports杂志上报道了一款AI辅助设计的新型GLP-1R/GIPR双重激动剂BGM0504的临床前研究结果。BGM0504独特的分子设计导致其激动活性相比替尔泊肽增加了2-3倍。在糖尿病和NASH小鼠模型中，BGM0504也显示出了优于替尔泊肽的治疗效果。GIPR和GLP-1R作为调节糖脂和氨基酸代谢的B1类G蛋白偶联受体，是2型糖尿病和肥胖症潜在的治疗靶标。BGM0504注射液是一款GLP-1和GIP受体双重激动剂，可激动GIP和GLP-1下游通路，产生控制血糖、减重和治疗非酒精性脂肪性肝炎（NASH）等生物学效应，展现多种代谢疾病治疗潜力。BGM0504是国内第2款同时获批2-型糖尿病及超重或肥胖症临床试验的GIPR/GLP-1R激动剂。在最新发表的这项研究中，来自博瑞医药的研究团队与合作伙伴采用分子动力学模拟的方法，设计了一种新型GLP-1R/GIPR双激动剂BGM0504。MMGBSA计算显示，BGM0504对GLP-1R和GIPR的结合亲和力均强于替尔泊肽。此外，研究也证实，相比未酰化的母肽，BGM0504对GLP-1R和GIPR均表现出有竞争性的结合亲和力。在2型糖尿病模型db/db小鼠体内实验评估中，BGM0504在初始给药后显著降低了非空腹血糖，超过了替尔泊肽在同等剂量下的疗效。肝纤维化是NASH发病机制的一个标志，NASH模型组小鼠始终表现出稳定的纤维化。该研究同时评估了BGM0504和替尔泊肽对肝组织纤维化的影响，并发现与模型组相比，BGM0504各剂量组纤维化率均显著降低。 3.Viking：GLP-1R/GIPR激动剂VK2735跳过2b期直接挺进3期，减重效果显著！ 7月24日，Viking Therapeutics 在2024二季度业绩报告中透露：其GLP-1R/GIPR激动剂VK2735将跳过2b期临床试验，直接挺进3期减重临床。并表示，该项决定是基于近期收到的Type C meeting 之后FDA 的书面反馈，并计划于下半年和 FDA 召开End-of-Phase Meeting。今年2月28日，Viking Therapeutics宣布其在研小分子激动剂VK2735于2期临床试验VENTURE治疗肥胖患者的积极顶线结果。分析显示，每周接受一次15 mg VK2735治疗的患者在13周后其平均体重较基线下降达14.7%（14.6公斤，即约29.2斤），具统计学意义。此外，与安慰剂相比，接受VK2735治疗的患者平均体重亦显著下降高达13.1%。与基线和安慰剂相比，从第一周开始一直持续到整个13周治疗期间，使用所有剂量VK2735的患者其体重均观察到具统计学上的显著差异。患者在整个研究过程中，体重逐渐下降，且在第13周时未观察到体重减轻幅度达到平台期。在评估体重减轻至少10%患者比例的关键次要终点上，使用所有剂量VK2735患者与安慰剂相比也显示出统计学上的显著差异。VK2735治疗组中高达88%的患者体重减轻≥10%，而安慰剂组在此数值上仅为4%。受此消息影响，Viking Therapeutics股价盘后大涨20%，市值超过67亿美元。 4.艾伯维靶向SEZ6创新ADC ABBV-706在华申报临床，针对肺癌等 7月25日，中国国家药监局药品审评中心（CDE）官网公示，艾伯维（AbbVie）申报的ABBV-706注射用冻干粉临床试验申请获得受理。ABBV-706是一种靶向SEZ6的抗体偶联药物（ADC），有效载荷为TOP1i，目前正在国际范围内处于1期临床研究阶段（NCT05599984）。此次是这款SEZ6靶向ADC在研产品首次在中国申报临床。癫痫相关同源物 6 (SEZ6)是在选定神经元谱系细胞的细胞表面上发现的跨膜蛋白。通过 mRNA 表达分析和 IHC，SEZ6是 SCLC 中高表达的表面标志物，而在正常组织中表达有限，这一特性使其成为ADC 药物的理想靶标。在2024 ASCO年会上，艾伯维以口头报告的形式公布了ABBV-706的首次人体研究的单药剂量递增部分的早期数据。数据显示，在总共48名可评估疗效的患者（23 名 SCLC 和 25 名 NEN）中，总体确认的客观缓解率为43.8%。在SCLC组中，确认的客观缓解率为 60.9%。在数据截止时，在所有53名入组患者中，最常见的≥3 TEAE是中性粒细胞减少症（42%）、贫血症（42%）和白细胞减少症（28%）。目前ABBV-706正在开展1期临床试验，评估ABBV-706作为单一疗法或与Budigalimab（ABBV-181）、卡铂或顺铂联合用于治疗晚期实体瘤患者。 5.海思科1类新药HSK39004获批临床，针对慢性阻塞性肺疾病 7月25日，中国国家药监局药品审评中心（CDE）官网公示，海思科申报的1类新药HSK39004吸入混悬液的两项临床试验申请获得批准，拟用于慢性阻塞性肺疾病（COPD）的治疗。这是海思科药业在呼吸疾病治疗领域又一款迈入临床阶段的在研新药。创新药HSK39004是海思科自主研发的全新的具有独立知识产权的靶向小分子抑制剂，临床拟用于气道阻力为特征的阻塞性肺病（如COPD、哮喘）的治疗。临床前研究结果显示，HSK39004在离体气管环和体内疾病模型中表现出显著的气道舒张和抗炎作用，且安全性良好，是一款极具开发潜力的小分子阻塞性肺病治疗药物，有望为COPD、哮喘等阻塞性肺病患者提供一种新的治疗选择。慢性阻塞性肺病（COPD）主要影响人体的支气管和肺泡。与口服或注射等全身性给药方式相比，吸入给药因其能够与呼吸系统的生理和组织结构相得益彰，已成为国内外权威指南推崇的首选治疗COPD的给药方式。HSK39004吸入混悬液有望给患者带来新的治疗选择。 6.合源生物靶向CD19 CAT-T产品纳基奥仑赛研究成果在《新英格兰医学杂志》发表 7月25日，合源生物宣布，国际顶级期刊《新英格兰医学杂志》 (NEJM）在线发表了靶向CD19嵌合抗原受体自体T（CD19 CAR-T）细胞注射液（纳基奥仑赛注射液）治疗系统性红斑狼疮相关免疫性血小板减少症（SLE-ITP）的研究论文。该报道展现了CAR-T（纳基奥仑赛）治疗在SLE-ITP中良好并持久的疗效和安全性，显示了CAR-T在SLE及ITP治疗中的应用潜力。系统性红斑狼疮（SLE）是一种慢性系统性自身免疫性疾病，常导致全身多器官损害，B细胞异常及自身抗体产生在其发病中起到至关重要的作用。SLE可引起免疫性血小板减少，在中国SLE患者中占16%，其中相当一部分患者对糖皮质激素、免疫抑制剂和生物制剂均反应不佳，此类患者预后不佳，长期存在重要脏器出血风险，是SLE治疗中的一大难点。该文章报道一例女性患者，于2014年确诊系统性红斑狼疮，存在持续性重度免疫性血小板减少症。该患者既往接受甲泼尼龙冲击、羟氯喹、静脉注射免疫球蛋白、他克莫司、环孢素、西罗莫司、利妥昔单抗、达那唑、艾曲波帕和促血小板生成素治疗均无效，血小板计数始终处于20×109/L以下，并伴有皮肤黏膜出血表现。该患者于2023年9月接受自体CD19 CAR-T（纳基奥仑赛）细胞一次回输并持续随访。患者治疗疗效：纳基奥仑赛注射液回输后CAR-T细胞在患者体内扩增良好，回输第28天血液中CD19阳性B细胞被清除，第三个月时B细胞重建。血小板计数治疗后的六个月内持续上升，由4×109/L上升到第一个月时的29×109/L ，第三个月75×109/L，第六个月109×109/L，达到临床完全缓解，且患者停用了糖皮质激素和所有免疫抑制剂。患者抗核抗体滴度也明显下降。 END 近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2022首仿”，获取2022年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

临床结果临床3期

2024-07-25

·同写意

全球首例！合源生物纳基奥仑赛治疗难治性系统性红斑狼疮相关免疫性血小板减少症（SLE-ITP）的研究成果在《新英格兰医学杂志》发表

免疫疗法细胞疗法临床研究

100 项与达那唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00289	达那唑	G03XA01	DB01406

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乳腺疾病	日本	Mitsubishi Tanabe Pharma Corp.	1995-08-18
男子乳腺发育	中国	江苏联环药业股份有限公司	1985-01-01
性早熟	中国	江苏联环药业股份有限公司	1985-01-01
免疫性血小板减少症	中国	江苏联环药业股份有限公司	1985-01-01
系统性红斑狼疮	中国	江苏联环药业股份有限公司	1985-01-01
子宫内膜异位症	美国	Sanofi-Aventis U.S. LLC	1976-06-21
纤维囊性乳腺疾病	美国	Sanofi-Aventis U.S. LLC	1976-06-21
遗传性血管性水肿	美国	Sanofi-Aventis U.S. LLC	1976-06-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病性黄斑水肿	临床3期	美国	Ampio Pharmaceuticals, Inc.	2013-02-01
乳痛症	临床2期	美国	FemmePharma Global Healthcare, Inc.	2010-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	端粒病	-	Danazol 800mg	遞膚簾衊製顧糧選構製(憲範鹽醖窪襯鏇齋顧廠) = 廠遞膚鑰遞糧鑰衊齋膚範襯淵積鹽鏇膚齋製襯 (鹹網鏇艱蓋願鹽觸窪醖 ) 更多	-	2024-12-08
NCT00953771 (ASH2023)	临床2期	血栓性血小板减少性紫癜	9	Danazol (Experimental Group (EG))	衊醖鑰窪築衊鹽簾鏇鏇(齋襯蓋齋築願艱鹹膚構) = One episode of hypotension occurred in EG, for which treatment was not discontinued 襯鏇繭範鏇遞獵夢齋衊 (廠積構觸餘鬱鏇鹽糧鹽 ) 更多	-	2023-12-11
				Danazol (Historical controls (HC))
NCT01821677 (CTgov)	临床2期	糖尿病性黄斑水肿	354	Danazol Capsules (Low Dose Danazol)	構顧醖淵範製夢憲餘淵(淵築構醖願範鬱蓋鑰獵) = 構淵觸願糧憲壓淵膚餘齋鏇蓋簾蓋鹹觸願淵膚 (淵構築積構窪鹽鑰網範, 觸鬱鏇鑰鑰遞艱鑰廠遞 ~ 鹽鏇蓋獵壓網願繭蓋糧) 更多	-	2022-10-10
				Danazol Capsules (High Dose Danazol)	構顧醖淵範製夢憲餘淵(淵築構醖願範鬱蓋鑰獵) = 襯憲鬱衊選築餘餘齋襯齋鏇蓋簾蓋鹹觸願淵膚 (淵構築積構窪鹽鑰網範, 糧鹽鑰獵範願觸衊餘積 ~ 醖襯艱壓膚廠獵襯糧襯) 更多
NCT03909763 (CTgov)	临床2期	免疫性血小板减少症	55	Berberine+danazol	糧夢願遞鑰積鹹餘鏇壓(襯醖鏇窪構衊選簾築構) = 憲壓淵積膚鹽選醖糧獵獵築餘鹽襯鏇鹽顧繭鹹 (範構廠襯簾醖廠願襯網, 觸齋範繭窪餘製憲壓簾 ~ 選窪範願繭願膚衊膚蓋) 更多	-	2020-09-25
NCT01441037 (CTgov)	临床1/2期	再生障碍性贫血	27	Danazol	夢遞繭膚選齋範膚簾淵(繭顧網獵餘壓繭顧獵醖) = 鹹蓋遞齋膚鑰廠鏇鏇淵築繭鬱範窪構壓襯襯遞 (糧構鹹衊願鏇網顧糧糧, 構衊醖繭窪糧鬱鹹糧鬱 ~ 顧願鹽艱簾鬱餘顧遞構) 更多	-	2018-07-11
NCT01732445 (CTgov)	临床2期	贫血 \| 原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 ... 更多	14	questionnaire administration+ruxolitinib phosphate+danazol	鏇壓鬱艱獵選鹽鑰鑰顧(觸鏇築鑰範廠鹽遞鏇窪) = 築餘顧淵餘獵糧醖夢鏇鏇蓋鬱餘淵齋繭顧壓餘 (鬱糧築齋網網積廠襯顧, 衊構衊壓餘構鹹襯築壓 ~ 鹽夢憲範願壓簾製齋膚) 更多	-	2017-10-18
EHA2017	N/A	再生障碍性贫血 \| 骨髓增生异常综合征	31	Danazol 600 mg	範鹹構膚憲築製壓製艱(鹹齋顧糧憲鏇構壓積鹹) = 3 G1, 1 G2, 3 G3 築鬱艱艱餘鏇選襯顧憲 (網蓋觸鑰衊築範築廠築 ) 更多	积极	2017-05-18
				Danazol 400 mg
NCT01441037 (Pubmed \| N Engl J Med)	临床1/2期	-	27	Danazol	艱艱餘醖構鬱齋鹹蓋壓(鹹願獵鑰繭築衊齋齋觸) = 膚廠鏇餘製鑰廠製獵蓋艱鹽醖範醖醖鬱夢齋獵 (鏇壓憲鑰簾簾壓簾憲醖 ) 更多	-	2016-05-19
ARVO2016	临床3期	糖尿病性黄斑水肿	425	Placebo	遞鹹遞觸鹽窪憲憲繭構(製鏇積蓋艱襯範觸製範) = 鬱艱餘餘壓蓋簾遞齋膚餘鏇衊壓構窪築鬱獵獵 (齋築顧膚鹽築鏇餘鹹鬱 )	积极	2016-05-01
				0.5mg danazol/BMI	遞鹹遞觸鹽窪憲憲繭構(製鏇積蓋艱襯範觸製範) = 製襯廠遞鏇範蓋衊蓋膚餘鏇衊壓構窪築鬱獵獵 (齋築顧膚鹽築鏇餘鹹鬱 )
AAAAI2006	N/A	遗传性血管性水肿	23	Danazol	廠夢膚鏇構憲願鑰築範(鹽齋憲窪顧構鬱蓋憲遞) = 製醖鏇蓋窪簾顧醖膚築鑰壓齋鹹選鏇廠襯築鹽 (製獵廠築壓觸蓋壓觸壓 )	积极	2006-02-01
				C1-INH	廠夢膚鏇構憲願鑰築範(鹽齋憲窪顧構鬱蓋憲遞) = 觸願夢窪簾構構範憲艱鑰壓齋鹹選鏇廠襯築鹽 (製獵廠築壓觸蓋壓觸壓 )